GlassScriptPhysician profile
Muhammad Farooq Asghar
NPI 1447416342
$6,171.80
in general payments reported to CMS, 2019-2025
32 companies · $641 in 2025
The $641 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $52.93 · 2021: $22.93 · 2022: $2,209 · 2023: $1,709 · 2024: $1,311 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,325 · Travel and Lodging: $271 · Education: $64.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,325.09 |
| Travel and Lodging | $271.25 |
| Education | $64.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $1,795.91 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $952.29 | 2021-2025 | Breztri, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $784.84 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Genzyme Corporation | $419.11 | 2022-2025 | |
| Intuitive Surgical, INC. | $271.25 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $252.69 | 2023-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.28 | 2022-2025 | Ofev, Spiriva Respimat |
| Electromed, INC. | $164.49 | 2022-2024 | Smartvest |
| Axsome Therapeutics, INC. | $155.87 | 2023-2025 | Sunosi |
| Pfizer INC. | $143.66 | 2023-2024 | |
| Mylan Specialty L.P. | $103.62 | 2023-2024 | Yupelri |
| Philips North America LLC | $94.32 | 2019-2023 | |
| Resmed Corp | $92.80 | 2020-2024 | |
| Baxter Healthcare | $81.53 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Sunovion Pharmaceuticals INC. | $77.90 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $63.75 | 2023-2024 | |
| Ethicon INC. | $61.14 | 2022 | |
| United Therapeutics Corporation | $46.46 | 2024-2025 | Tyvaso, Tyvaso |
| Harmony Biosciences LLC | $44.86 | 2023 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $41.86 | 2023 | Glassia |
| Avadel Cns Pharmaceuticals, LLC | $41.40 | 2024 | Lumryz |
| Grifols USA, LLC | $36.51 | 2020 | |
| Janssen Pharmaceuticals, INC | $34.79 | 2019-2022 | |
| Shire North American Group INC | $34.48 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $33.07 | 2023 | Opsumit |
| Veran Medical Technologies, INC. | $27.78 | 2019 | |
| Merck Sharp & Dohme LLC | $23.98 | 2024 | Recarbrio, Dificid, Zerbaxa |
| Verona Pharma, INC. | $23.74 | 2025 | Ohtuvayre |
| Insmed, INC. | $19.74 | 2024 | Arikayce |
| Viatris Specialty LLC | $18.18 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $14.47 | 2022 | |
| Itamar Medical INC | $11.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Asghar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.